Effect of Low Intensity Pulsed Ultrasound on Involution of the Uterus Postpartum

November 12, 2026 updated by: Alaa Hisham Ibrahim Zamzam, Cairo University

The aim of this study is to determine the effect of low intensity pulsed ultrasound on subinvolution of the uterus postpartum.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Low intensity pulsed ultrasound (LIPUS) is a safe and effective treatment for uterine involution. It contributes to uterine contraction after cesarean section, shortens the duration of lochia and relieves postpartum pain, thus decreasing the incidence of poor uterine involution, reducing vaginal bleeding and decreasing fundal height which was assessed using fundal level test. LIPUS can increase the frequency and amplitude of spontaneous contractions of the uterus in postpartum women. Therefore, this study will be conducted to investigate the effect of LIPUS on subinvolution through decreasing the incidence of delayed uterine atony and postpartum hemorrhage in postpartum women whether they had vaginal or cesarean delivery. There is no previous study illustrating the effect of LIPUS on subinvolution by using an objective measurement, so in this study, the effect of LIPUS will be measured using an evaluative ultrasonography. This study will add a new piece of information that maybe helpful for women suffering from this condition and may help the field of physical therapy for women health.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Postpartum women with uterine subinvolution (delivered vaginally or through caesarean section).
  • All women are regularly lactating.
  • Their age will be ranged from 25 to 40 years old.
  • Their body mass index will be ranged from 20 - 30 kg/m².

Exclusion Criteria:

  • History of abdominal surgeries except for cesarean section.
  • Abdominal skin diseases, lesions, injuries, burns or open wounds.
  • Any malignant tumors or fibroids.
  • Coagulation disorders.
  • History of chronic diseases such as diabetes, hypertension, cardiovascular and pulmonary diseases.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Postpartum exercise program group

The participant will follow a program of postpartum exercises, 30 minutes, 3 sessions / week for 6 weeks.

The postpartum exercise program will begin with 6-minute warm up stretching exercises for hamstrings, hip adductors, gluteal muscles, quadriceps, calves and soleus. The main phase of exercise program will consist of core stabilization exercises, done for 10 repetition and repeated twice / day, total of 30 minutes, 3 sessions / week for 6 weeks. It will include abdominal breathing exercise, bridge exercises and kneeling abdominal exercises.

Experimental: Low intensity pulsed ultrasound and postpartum exercise program group

The participants will receive low intensity pulsed ultrasound with frequency 0.7-1.0 MHz for 30 minutes, 3 sessions / week for 6 weeks, in addition to the same program of postpartum exercises.

The postpartum exercise program will begin with 6-minute warm up stretching exercises for hamstrings, hip adductors, gluteal muscles, quadriceps, calves and soleus. The main phase of exercise program will consist of core stabilization exercises, done for 10 repetition and repeated twice / day, total of 30 minutes, 3 sessions / week for 6 weeks. It will include abdominal breathing exercise, bridge exercises and kneeling abdominal exercises.

The participants will receive therapeutic ultrasound using the following parameters: frequency 0.7-1 MHz, with intensity <3 W/cm2 for 30 min, 6 hours post vaginal delivery and 24 hours post cesarean section.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Uterine involution
Time Frame: 6 weeks

A diagnostic ultrasound device (EDAN, DUS 60, China), with 2.5-MHz convex transducer will be used to trace fundus level and progression of uterine involution before and after the intervention for all participants in both groups.

6 weeks
Pain Intensity
Time Frame: 6 weeks

Visual analogue scale (VAS) will be used to assess pain intensity. It is a numeric scale, usually represents a horizontal line, 100 mm (10cm) in length, representing the severity of symptoms from 0 "no symptoms" to 10 "very severe symptoms . VAS is a valuable and reliable tool for the documentation of symptom severity, treatment effectiveness.

6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Hossam H Kamel, Professor, Al-Azhar University
  • Study Chair: Hala M Omara, Professor, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

February 20, 2027

Study Completion (Estimated)

February 28, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • P.T.REC/012/006454

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.